Cue Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $27,136 | $22,459 |
| Accounts receivable | 5,546 | 945 |
| Deposits, current portion | 1,093 | 929 |
| Prepaid expenses and other current assets | 1,309 | 805 |
| Foreign withholding tax receivable | 1,899 | — |
| Total current assets | 36,983 | 25,138 |
| Property and equipment, net | 241 | 471 |
| Operating lease right-of-use asset | 4,074 | 4,370 |
| Deposits, net of current portion | 666 | 1,955 |
| Restricted cash | 154 | 152 |
| Other long term assets | 94 | 105 |
| Total assets | $42,212 | $32,191 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,948 | $2,823 |
| Accrued expenses | 1,611 | 2,908 |
| Research and development contract liability, current portion | 5,335 | 85 |
| Operating lease liabilities, current portion | 1,911 | 3,540 |
| Current portion of long-term debt, net | — | 4,333 |
| Other current payable | 689 | — |
| Total current liabilities | 13,494 | 13,689 |
| Operating lease liabilities, net of current portion | 2,286 | 1,003 |
| Total liabilities | $15,780 | $14,692 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 300,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 96,621,218 and 61,819,101 shares issued and outstanding at December 31, 2025 and 2024, respectively | 97 | 62 |
| Additional paid-in capital | 394,801 | 359,301 |
| Accumulated deficit | (368,466) | (341,864) |
| Total stockholders’ equity | 26,432 | 17,499 |
| Total liabilities and stockholders’ equity | $42,212 | $32,191 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.